Department of Nephrology, Medical School, Fatih University, Ankara, Turkey.
Ren Fail. 2010;32(9):1115-7. doi: 10.3109/0886022X.2010.509898.
In patients with renal artery stenosis (RAS), the inhibition of renin-angiotensin-aldosterone system can cause deterioration of renal function. Here we present a 75-year-old man who developed acute renal failure after olmesartan treatment. Following discontinuation of olmesartan, his renal functions normalized. His renal Doppler ultrasonography and renal angiography showed findings consistent with bilateral RAS. In this case, unlike those previously reported, renal failure developed with olmesartan for the first time and after only a single dose, which is thought to be a new, safe, and tolerable antihypertensive agent. This is a well-defined effect of angiotensin-converting enzyme inhibitors, in patients with RAS. Also with the increasing use of angiotensin II receptor blockers (ARBs), renal failure associated with ARBs in patients with RAS is rising. The use of olmesartan also requires caution and close follow-up of renal functions for patients who have risk factors.
在肾动脉狭窄(RAS)患者中,肾素-血管紧张素-醛固酮系统的抑制可导致肾功能恶化。在此,我们介绍一位 75 岁男性,他在服用奥美沙坦后发生急性肾衰竭。停用奥美沙坦后,他的肾功能恢复正常。他的肾脏多普勒超声和血管造影显示双侧 RAS 的表现一致。在这种情况下,与之前报道的情况不同,这是首例首次使用且仅使用单剂量奥美沙坦后发生的肾衰竭,这被认为是一种新型、安全且耐受良好的降压药物。这是血管紧张素转换酶抑制剂在 RAS 患者中明确的作用。随着血管紧张素 II 受体阻滞剂(ARB)的应用越来越广泛,RAS 患者使用 ARB 相关的肾衰竭也在增加。对于有危险因素的患者,使用奥美沙坦也需要谨慎,并密切关注肾功能。